InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,129.60
(
-0.24%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.16
(
-0.37%
)
Bitcoin
60,945.33
(
0.21%
)
Post# of 252388
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119931
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 145237

Friday, 09/07/2012 10:27:26 AM

Friday, September 07, 2012 10:27:26 AM

Post# of 252388
JNJ resubmits Xarelto NDA in PCI sub-indication of ACS:

http://finance.yahoo.com/news/janssen-research-development-submits-complete-120000837.html

This NDA, which is separate from the rejected Xarelto NDA in ACS per se, was voluntarily withdrawn by JNJ in July 2012 (#msg-77346396). In today’s PR, JNJ confirms that the additional information in the resubmission for PCI is in response to questions raised by the FDA in the June CRL rejecting the NDA in ACS (#msg-76856261).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up